Merus (MRUS)
(Delayed Data from NSDQ)
$56.55 USD
-1.10 (-1.91%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $56.49 -0.06 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Merus N.V. [MRUS]
Reports for Purchase
Showing records 141 - 160 ( 174 total )
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
3Q18 Financials; Data-Rich 2H19 Expected for MCLA-128, 117 and ?145
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Biotechnology - ESMO 2018 Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Unclassified
Undervalued with Several Catalysts Playing out in Near Term
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Unclassified
1Q18 Financials; Adding MCLA-158 to our Valuation as it Enters the Clinic
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Unclassified
4Q17 Financials; MCLA-128 Combos Underway, Monotherapy Update at ESMO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Unclassified
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Unclassified
MCLA-117, ''158 Edge Closer to Clinic in the US; New Platform Collaboration
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Unclassified
3Q, MCLA-128 on Track to Enter Ph 2 before YE
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Unclassified
2Q Financials; Steady Clinical Progress to Date, Catalysts by Year End
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Unclassified
1Q Financials, Valuation Does Not Reflect Pipeline and Platform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Unclassified
MCLA-128 Impresses with Breast Cancer Results at ASCO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Merus N.V.
Industry: Unclassified
Week Ahead: Focus Calls
Provider: WEDBUSH SECURITIES INC.
Company: Merus N.V.
Industry: Unclassified
ASCO 2017 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D